Stempeutics Research, a part of the Manipal Education and Medical Group (MEMG), has received process patent from the State Intellectual Property Office of China (SIPO) for its novel stem-cell based drug Stempeucel for the treatment of Critical Limb Ischemia (CLI), a progressive form of peripheral arterial disease.